Fortress Biotech Pref A's chart exhibits Bollinger Bands narrowing and bearish Marubozu pattern.
ByAinvest
Wednesday, Oct 1, 2025 2:04 pm ET2min read
FBIO--
The ATP assay market is primarily influenced by the growing need for real-time cellular analysis tools in the healthcare sector. Precision medicine and personalized treatments are becoming increasingly popular, making ATP assays essential for diagnostics, research, and pharmaceutical development. These assays provide accurate, real-time data on cell viability and energy metabolism, crucial for early-stage drug screening and cytotoxicity studies [1].
The consumables segment dominated the market in 2024, driven by the continuous and indispensable role of assay kits, detection reagents, and microplates in laboratory routines. High consumption in pharmaceutical R&D, microbial testing, and quality assurance procedures ensures strong demand across all stages of the research and production process [1].
Cell-based ATP assays are expected to grow at an 8% CAGR through 2034, thanks to their ability to deliver consistent, quantitative results with minimal sample prep. Their compatibility with various detection systems and speed make them ideal for large-scale workflows in biotech, academic, and clinical laboratories [1].
Pharmaceutical and biotech companies held a 54.5% share in 2024, driven by strong investment in cell-based therapy development and a well-established innovation ecosystem. These companies are leading the adoption of ATP assays for screening, validation, and safety evaluation purposes, particularly as the industry shifts toward biologics, gene therapies, and customized treatments [1].
Leading players in the U.S. ATP Assay Market include Promega, Thermo Fisher Scientific, Biotium, Danaher, Cayman Chemical, Merck, Revvity, Cell Signaling Technology, Charm Sciences, Lonza, Berthold Technologies, Agilent Technologies, Abcam, and 3M Company. These companies are enhancing their market presence through innovation, product portfolio expansion, strategic collaborations, and digital integration [1].
The report also highlights industry trends, key growth drivers, challenges, future opportunities, and the regulatory landscape. It provides a comprehensive market analysis, including Porter's Five Forces and PESTEL analysis, market size, segmentation, and regional forecasts. In-depth company profiles, business strategies, financial insights, and SWOT analysis are also included [1].
In conclusion, the U.S. ATP Assay Market is poised for significant growth, driven by advancements in precision medicine, increasing demand for real-time cellular analysis tools, and strong support from pharmaceutical and biotech companies. The market's future outlook is promising, with a focus on innovation, product diversification, and strategic collaborations [1].
FBIOP--
According to the 15-minute chart for Fortress Biotech Pref A, the Bollinger Bands have narrowed, and a bearish Marubozu was observed on October 1, 2025, at 14:00. This suggests that the magnitude of price fluctuations is decreasing, indicating control by sellers and a continuation of bearish momentum.
The U.S. ATP Assay Market has shown significant growth, driven by increasing demand for real-time cellular analysis tools and precision medicine adoption. According to a recent report by ResearchAndMarkets.com, the market was valued at USD 1.5 billion in 2024 and is projected to grow at a CAGR of 7.6% to reach USD 3.1 billion by 2034 [1].The ATP assay market is primarily influenced by the growing need for real-time cellular analysis tools in the healthcare sector. Precision medicine and personalized treatments are becoming increasingly popular, making ATP assays essential for diagnostics, research, and pharmaceutical development. These assays provide accurate, real-time data on cell viability and energy metabolism, crucial for early-stage drug screening and cytotoxicity studies [1].
The consumables segment dominated the market in 2024, driven by the continuous and indispensable role of assay kits, detection reagents, and microplates in laboratory routines. High consumption in pharmaceutical R&D, microbial testing, and quality assurance procedures ensures strong demand across all stages of the research and production process [1].
Cell-based ATP assays are expected to grow at an 8% CAGR through 2034, thanks to their ability to deliver consistent, quantitative results with minimal sample prep. Their compatibility with various detection systems and speed make them ideal for large-scale workflows in biotech, academic, and clinical laboratories [1].
Pharmaceutical and biotech companies held a 54.5% share in 2024, driven by strong investment in cell-based therapy development and a well-established innovation ecosystem. These companies are leading the adoption of ATP assays for screening, validation, and safety evaluation purposes, particularly as the industry shifts toward biologics, gene therapies, and customized treatments [1].
Leading players in the U.S. ATP Assay Market include Promega, Thermo Fisher Scientific, Biotium, Danaher, Cayman Chemical, Merck, Revvity, Cell Signaling Technology, Charm Sciences, Lonza, Berthold Technologies, Agilent Technologies, Abcam, and 3M Company. These companies are enhancing their market presence through innovation, product portfolio expansion, strategic collaborations, and digital integration [1].
The report also highlights industry trends, key growth drivers, challenges, future opportunities, and the regulatory landscape. It provides a comprehensive market analysis, including Porter's Five Forces and PESTEL analysis, market size, segmentation, and regional forecasts. In-depth company profiles, business strategies, financial insights, and SWOT analysis are also included [1].
In conclusion, the U.S. ATP Assay Market is poised for significant growth, driven by advancements in precision medicine, increasing demand for real-time cellular analysis tools, and strong support from pharmaceutical and biotech companies. The market's future outlook is promising, with a focus on innovation, product diversification, and strategic collaborations [1].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet